Atea Pharmaceuticals Reports Positive Phase 3 C-BEYOND Trial Results and Q3 2026 Financials
Atea Pharmaceuticals (AVIR) announced successful results from its Phase 3 C-BEYOND clinical trial for hepatitis C treatment. The study met its primary endpoint with a 94% sustained virologic response (SVR) rate at week 24, demonstrating non-inferiority to the current standard of care. Notably, the regimen showed strong performance in non-cirrhotic patients using an abbreviated 8-week duration compared to the traditional 12-week regimen. Financially, Atea reported a net loss of $32.2 million for the quarter, an improvement from the previous year's $42.0 million loss. The company maintains a strong liquidity position with $191.2 million in cash and marketable securities, providing a projected runway into mid-2028. This stability is bolstered by a new $200 million credit facility from Hercules Capital to support the upcoming BEM/RZR commercial launch.
Tickers: $HTGC
Topics: Cash Runway Clinical Trial Results Financial Performance SVR Rate